Novel Drug Being Developed for Cancer Indications and HIV Prevention Demonstrates Best-in-Class Potency

OTTAWA, Ontario, July 23, 2019 (Newswire.com) – ​​Orion Biotechnology Canada Ltd. today announced that In vitro potency assessment of their lead compound, OB-002, has demonstrated that the chemokine analogue is more potent than other CCR5 antagonists in development for HIV prevention and cancer indications. Inhibitory potency of OB-002 was compared with maraviroc (Selzentry® or Celsentri®), … Read moreNovel Drug Being Developed for Cancer Indications and HIV Prevention Demonstrates Best-in-Class Potency

Orion Biotechnology’s CCR5 Blocker OB-002 Shows Strong Efficacy in a New Preclinical Model of Multiple Sclerosis

OTTAWA, Ontario, July 2, 2019 (Newswire.com) – Orion Biotechnology Canada Ltd., today announced the publication of preclinical data evaluating the efficacy of OB-002 (5P12-RANTES) in a murine model of multiple sclerosis in Science Translation Medicine [1]. Viral infection early in life is a key element in determining the risk of subsequent development of multiple sclerosis … Read moreOrion Biotechnology’s CCR5 Blocker OB-002 Shows Strong Efficacy in a New Preclinical Model of Multiple Sclerosis

contact us

Leave  us a message and we will try to respond by the next business day

ORION Logo Pantone(375x133)

Our Headquarters

343 Preston Street

11th floor,

Ottawa, ON K1S 1N4

CANADA

info@orionbiotechnology.com

contact us

Leave  us a message and we will try to respond by the next business day

ORION Logo Pantone(375x133)

Our Headquarters

343 Preston Street

11th floor,

Ottawa, ON K1S 1N4

CANADA

info@orionbiotechnology.com